Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Research Design | 30 | 2025 | 6210 | 3.550 |
Why?
|
Bayes Theorem | 21 | 2024 | 2353 | 2.850 |
Why?
|
Glioblastoma | 17 | 2023 | 3461 | 2.540 |
Why?
|
Clinical Trials as Topic | 19 | 2025 | 8048 | 1.690 |
Why?
|
Information Dissemination | 5 | 2024 | 1142 | 1.490 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2024 | 329 | 1.460 |
Why?
|
Randomized Controlled Trials as Topic | 19 | 2025 | 10393 | 1.360 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2022 | 638 | 1.080 |
Why?
|
Probability | 5 | 2023 | 2476 | 0.900 |
Why?
|
Brain Neoplasms | 13 | 2023 | 9108 | 0.880 |
Why?
|
Medical Futility | 2 | 2022 | 136 | 0.850 |
Why?
|
Data Interpretation, Statistical | 6 | 2018 | 2698 | 0.850 |
Why?
|
Maximum Tolerated Dose | 2 | 2024 | 896 | 0.810 |
Why?
|
Models, Statistical | 8 | 2024 | 5098 | 0.790 |
Why?
|
Random Allocation | 4 | 2023 | 2394 | 0.730 |
Why?
|
Computer Simulation | 14 | 2025 | 6260 | 0.720 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2021 | 187 | 0.710 |
Why?
|
Biometry | 2 | 2014 | 571 | 0.660 |
Why?
|
Drugs, Investigational | 1 | 2021 | 211 | 0.630 |
Why?
|
Medical Oncology | 4 | 2023 | 2341 | 0.600 |
Why?
|
Informed Consent | 1 | 2024 | 1010 | 0.580 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 11872 | 0.570 |
Why?
|
Carnitine | 1 | 2018 | 253 | 0.570 |
Why?
|
Kaplan-Meier Estimate | 7 | 2021 | 6513 | 0.540 |
Why?
|
Benchmarking | 1 | 2023 | 1056 | 0.540 |
Why?
|
Inheritance Patterns | 1 | 2018 | 344 | 0.520 |
Why?
|
Antineoplastic Agents | 5 | 2024 | 13650 | 0.510 |
Why?
|
Algorithms | 12 | 2024 | 14098 | 0.500 |
Why?
|
Tuberculosis, Multidrug-Resistant | 3 | 2021 | 941 | 0.480 |
Why?
|
Multiple Myeloma | 10 | 2025 | 5186 | 0.480 |
Why?
|
Antitubercular Agents | 4 | 2021 | 1380 | 0.480 |
Why?
|
Neoplasms | 9 | 2025 | 22350 | 0.470 |
Why?
|
Immunotherapy | 4 | 2022 | 4745 | 0.450 |
Why?
|
Survival Analysis | 6 | 2021 | 10092 | 0.440 |
Why?
|
Neurology | 1 | 2021 | 785 | 0.430 |
Why?
|
Breast Neoplasms | 15 | 2021 | 21178 | 0.430 |
Why?
|
Shock, Septic | 1 | 2018 | 772 | 0.390 |
Why?
|
Humans | 93 | 2025 | 767040 | 0.390 |
Why?
|
Proportional Hazards Models | 6 | 2021 | 12536 | 0.380 |
Why?
|
Waldenstrom Macroglobulinemia | 4 | 2022 | 1076 | 0.370 |
Why?
|
Electronic Health Records | 3 | 2023 | 4881 | 0.350 |
Why?
|
Pedigree | 1 | 2018 | 4539 | 0.350 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 2 | 2023 | 176 | 0.350 |
Why?
|
Computational Biology | 3 | 2020 | 3567 | 0.330 |
Why?
|
Head and Neck Neoplasms | 2 | 2020 | 2930 | 0.310 |
Why?
|
Receptor, erbB-2 | 7 | 2021 | 2599 | 0.300 |
Why?
|
Ovarian Neoplasms | 3 | 2021 | 4903 | 0.280 |
Why?
|
Endpoint Determination | 5 | 2017 | 592 | 0.280 |
Why?
|
Alleles | 1 | 2018 | 6893 | 0.280 |
Why?
|
Paclitaxel | 4 | 2021 | 1728 | 0.270 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6844 | 0.260 |
Why?
|
Decision Making | 4 | 2023 | 3951 | 0.250 |
Why?
|
Sepsis | 1 | 2018 | 2605 | 0.230 |
Why?
|
Receptors, CXCR4 | 2 | 2019 | 729 | 0.230 |
Why?
|
Organophosphorus Compounds | 1 | 2024 | 209 | 0.210 |
Why?
|
Boron Compounds | 1 | 2025 | 195 | 0.210 |
Why?
|
Software | 2 | 2014 | 4472 | 0.210 |
Why?
|
Prospective Studies | 8 | 2022 | 54886 | 0.200 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2019 | 878 | 0.190 |
Why?
|
Glycine | 1 | 2025 | 670 | 0.190 |
Why?
|
Dexamethasone | 3 | 2025 | 1963 | 0.180 |
Why?
|
Neurofibromatosis 2 | 1 | 2024 | 387 | 0.180 |
Why?
|
Gene Expression Profiling | 3 | 2020 | 9532 | 0.170 |
Why?
|
Filgrastim | 1 | 2020 | 131 | 0.170 |
Why?
|
Camptothecin | 1 | 2023 | 599 | 0.170 |
Why?
|
Hematopoiesis | 3 | 2020 | 2056 | 0.170 |
Why?
|
Treatment Outcome | 14 | 2025 | 65295 | 0.160 |
Why?
|
Ketones | 1 | 2020 | 183 | 0.160 |
Why?
|
Furans | 1 | 2020 | 199 | 0.160 |
Why?
|
Paraproteinemias | 1 | 2022 | 251 | 0.160 |
Why?
|
Oxazoles | 2 | 2020 | 198 | 0.160 |
Why?
|
DNA Mismatch Repair | 1 | 2022 | 431 | 0.160 |
Why?
|
Uncertainty | 1 | 2024 | 765 | 0.160 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 212 | 0.150 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 388 | 0.150 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2902 | 0.140 |
Why?
|
Sample Size | 2 | 2017 | 845 | 0.140 |
Why?
|
Anilides | 1 | 2019 | 413 | 0.130 |
Why?
|
Respiratory Tract Diseases | 1 | 2022 | 744 | 0.130 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 614 | 0.130 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 1002 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9410 | 0.130 |
Why?
|
Models, Genetic | 2 | 2018 | 3445 | 0.130 |
Why?
|
Female | 34 | 2025 | 396660 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 975 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2020 | 581 | 0.130 |
Why?
|
Nitroimidazoles | 1 | 2016 | 118 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2022 | 5716 | 0.120 |
Why?
|
Patient Care | 1 | 2021 | 628 | 0.120 |
Why?
|
Voltage-Sensitive Dye Imaging | 1 | 2014 | 30 | 0.120 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1012 | 0.120 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2014 | 120 | 0.120 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1188 | 0.110 |
Why?
|
Cyclophosphamide | 1 | 2020 | 2227 | 0.110 |
Why?
|
Data Collection | 1 | 2023 | 3321 | 0.110 |
Why?
|
Doxorubicin | 1 | 2020 | 2229 | 0.110 |
Why?
|
BRCA2 Protein | 1 | 2018 | 802 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1085 | 0.110 |
Why?
|
Salvage Therapy | 1 | 2019 | 1271 | 0.100 |
Why?
|
Mutation | 6 | 2020 | 30211 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1097 | 0.100 |
Why?
|
Embryo, Mammalian | 2 | 2016 | 1676 | 0.100 |
Why?
|
Likelihood Functions | 1 | 2015 | 996 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1183 | 0.100 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 369 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 3044 | 0.100 |
Why?
|
BRCA1 Protein | 1 | 2018 | 1155 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2019 | 20169 | 0.090 |
Why?
|
Models, Biological | 2 | 2020 | 9464 | 0.090 |
Why?
|
Molecular Sequence Annotation | 1 | 2014 | 526 | 0.090 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 940 | 0.090 |
Why?
|
Survival Rate | 4 | 2020 | 12823 | 0.090 |
Why?
|
Disease Progression | 6 | 2025 | 13646 | 0.090 |
Why?
|
Pyridines | 2 | 2020 | 2890 | 0.090 |
Why?
|
Transplantation, Autologous | 3 | 2022 | 2118 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3212 | 0.090 |
Why?
|
Markov Chains | 1 | 2014 | 976 | 0.090 |
Why?
|
Particulate Matter | 1 | 2022 | 2621 | 0.080 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4560 | 0.080 |
Why?
|
Epidemiologic Methods | 1 | 2014 | 1326 | 0.080 |
Why?
|
Prognosis | 7 | 2020 | 29963 | 0.080 |
Why?
|
Risk | 4 | 2022 | 9606 | 0.080 |
Why?
|
Patient Participation | 1 | 2018 | 1444 | 0.080 |
Why?
|
Drug Discovery | 1 | 2017 | 1068 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2014 | 3797 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2006 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4256 | 0.080 |
Why?
|
Aged | 18 | 2025 | 171319 | 0.080 |
Why?
|
Point Mutation | 1 | 2014 | 1591 | 0.080 |
Why?
|
Life Expectancy | 1 | 2015 | 1248 | 0.080 |
Why?
|
Monte Carlo Method | 1 | 2014 | 1250 | 0.080 |
Why?
|
Receptors, Estrogen | 3 | 2020 | 2252 | 0.070 |
Why?
|
Male | 18 | 2025 | 364203 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3667 | 0.070 |
Why?
|
Middle Aged | 18 | 2025 | 223233 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2019 | 1639 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2019 | 3599 | 0.070 |
Why?
|
Asymptomatic Diseases | 2 | 2021 | 588 | 0.070 |
Why?
|
Cell Lineage | 1 | 2016 | 2575 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2020 | 4855 | 0.070 |
Why?
|
Genomics | 2 | 2020 | 5924 | 0.070 |
Why?
|
Environmental Exposure | 1 | 2022 | 4546 | 0.070 |
Why?
|
Genotype | 2 | 2018 | 13035 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 2047 | 0.060 |
Why?
|
Immunoglobulin M | 2 | 2022 | 1527 | 0.060 |
Why?
|
Databases, Factual | 1 | 2021 | 8068 | 0.060 |
Why?
|
Adult | 16 | 2025 | 223317 | 0.060 |
Why?
|
Receptors, Progesterone | 2 | 2020 | 1159 | 0.060 |
Why?
|
Tuberculosis | 1 | 2018 | 2011 | 0.060 |
Why?
|
Cross-Over Studies | 2 | 2022 | 2105 | 0.060 |
Why?
|
Palliative Care | 1 | 2020 | 3641 | 0.060 |
Why?
|
Recurrence | 2 | 2019 | 8504 | 0.060 |
Why?
|
Single-Cell Analysis | 1 | 2016 | 2538 | 0.060 |
Why?
|
Aged, 80 and over | 8 | 2025 | 59548 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5332 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2014 | 2744 | 0.060 |
Why?
|
Glioma | 1 | 2019 | 3502 | 0.060 |
Why?
|
Hearing Disorders | 1 | 2024 | 126 | 0.060 |
Why?
|
Stochastic Processes | 2 | 2015 | 359 | 0.060 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8535 | 0.050 |
Why?
|
Neoplasm Metastasis | 1 | 2014 | 4892 | 0.050 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2014 | 3610 | 0.050 |
Why?
|
Administration, Oral | 2 | 2024 | 4026 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14672 | 0.050 |
Why?
|
Quinazolines | 2 | 2020 | 1369 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 40154 | 0.050 |
Why?
|
Hippocampus | 1 | 2014 | 3777 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3552 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 630 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4787 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 3828 | 0.050 |
Why?
|
Immunologic Tests | 1 | 2021 | 101 | 0.050 |
Why?
|
MicroRNAs | 1 | 2017 | 3792 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8736 | 0.040 |
Why?
|
Premedication | 1 | 2021 | 245 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 8628 | 0.040 |
Why?
|
Neurofibromatoses | 1 | 2024 | 303 | 0.040 |
Why?
|
Risk Factors | 4 | 2022 | 74886 | 0.040 |
Why?
|
Artificial Intelligence | 1 | 2014 | 2666 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11217 | 0.040 |
Why?
|
Models, Immunological | 1 | 2021 | 516 | 0.040 |
Why?
|
Rifampin | 1 | 2021 | 350 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3530 | 0.040 |
Why?
|
Bone Marrow | 2 | 2019 | 2926 | 0.040 |
Why?
|
Neurilemmoma | 1 | 2024 | 522 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2017 | 2040 | 0.040 |
Why?
|
Benzylamines | 1 | 2019 | 251 | 0.040 |
Why?
|
Heterocyclic Compounds | 1 | 2019 | 245 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5702 | 0.040 |
Why?
|
Tumor Burden | 1 | 2024 | 1903 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11097 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2019 | 330 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 353 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39317 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 2952 | 0.040 |
Why?
|
Creatinine | 1 | 2023 | 1916 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2014 | 11657 | 0.030 |
Why?
|
Standard of Care | 1 | 2021 | 569 | 0.030 |
Why?
|
Young Adult | 5 | 2024 | 59980 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2021 | 862 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15645 | 0.030 |
Why?
|
Administration, Cutaneous | 1 | 2018 | 715 | 0.030 |
Why?
|
Purines | 1 | 2019 | 614 | 0.030 |
Why?
|
Gene Dosage | 1 | 2020 | 1211 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 1997 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 713 | 0.030 |
Why?
|
Heterozygote | 1 | 2022 | 2794 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 498 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12790 | 0.030 |
Why?
|
Melphalan | 1 | 2017 | 421 | 0.030 |
Why?
|
Aminopyridines | 1 | 2019 | 578 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2227 | 0.030 |
Why?
|
Karyotyping | 1 | 2017 | 1176 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2019 | 582 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2022 | 2201 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2023 | 81659 | 0.030 |
Why?
|
Databases as Topic | 1 | 2016 | 472 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1656 | 0.030 |
Why?
|
Risk Assessment | 3 | 2021 | 24299 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2022 | 1885 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2015 | 474 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 984 | 0.030 |
Why?
|
Immune System | 1 | 2019 | 799 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1592 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1139 | 0.030 |
Why?
|
Cohort Studies | 3 | 2022 | 41718 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 1837 | 0.030 |
Why?
|
Exosomes | 1 | 2017 | 417 | 0.020 |
Why?
|
Mice, SCID | 1 | 2017 | 2626 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2019 | 1349 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2019 | 1205 | 0.020 |
Why?
|
Breast | 1 | 2020 | 1972 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14476 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15424 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2015 | 1443 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 4572 | 0.020 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 1119 | 0.020 |
Why?
|
Indoles | 1 | 2017 | 1836 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3608 | 0.020 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2015 | 951 | 0.020 |
Why?
|
Mice | 4 | 2017 | 81912 | 0.020 |
Why?
|
Air Pollution | 1 | 2022 | 2378 | 0.020 |
Why?
|
Air Pollutants | 1 | 2022 | 2920 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4522 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5693 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10748 | 0.020 |
Why?
|
Sulfonamides | 1 | 2017 | 1982 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2019 | 3561 | 0.020 |
Why?
|
Radiology | 1 | 2021 | 2106 | 0.020 |
Why?
|
Health Personnel | 1 | 2021 | 3387 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3944 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7587 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9360 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5311 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 2429 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6777 | 0.020 |
Why?
|
Prevalence | 1 | 2022 | 15851 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2024 | 5859 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3700 | 0.010 |
Why?
|
Phenotype | 1 | 2022 | 16718 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6813 | 0.010 |
Why?
|
Animals | 4 | 2017 | 168965 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9513 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9612 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13485 | 0.010 |
Why?
|
Child | 2 | 2024 | 80771 | 0.010 |
Why?
|
Hospitalization | 1 | 2022 | 10815 | 0.010 |
Why?
|
Adolescent | 2 | 2024 | 89046 | 0.010 |
Why?
|
United States | 2 | 2022 | 72971 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 17097 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2017 | 22254 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 8940 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36582 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23621 | 0.010 |
Why?
|
Infant | 1 | 2015 | 36485 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 42606 | 0.010 |
Why?
|